Asia Pacific Molecular Diagnostics Market By Product & Services (Reagents & Kits, Instruments, Software & Services), Technology (Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, Hybridization, DNA Sequencing & Next-Generation Sequencing, Microarray), Application (Infectious Diseases, Oncology, Blood Screening, Genetic Tests, Microbiology), End User (Hospital & Academic Laboratories, Reference Laboratories)
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Asia Pacific Molecular Diagnostics Market
The Asia Pacific Molecular Diagnostics Market Size is anticipated to experience a growth of 11.4% CAGR during the forecast period (2016 - 2022).
Molecular Diagnostics is used to identify or monitor biomarkers associated with any particular diseases or conditions. This test could also help in detecting and quantifying the presence of specific bacteria and viruses. These devices help surgeons in deciding that which therapy would work best on different patients. Molecular Diagnostics detect the diseases by analyzing RNA (Ribonucleic Acid) or DNA (Deoxyribonucleic Acid) in humans. These diagnostics are mainly used for clinical testing devices that are supplied in clinics, hospitals, laboratories, and research institutes. Infectious diseases and Cancer is becoming
threat for the Asian region specifically India. According to the statistics in 2016, approximately 5.1 million people are living with HIV in Asian region. In 2015, there were an estimated 300,000 new infections in the Asia- Pacific. In Addition, Institute of Medical Research stated the estimation of Cancer, ?1.5 lakh breast cancer cases and 1 lakh cervix cancer, new cases were recorded in India. Personalized medicine is also becoming trend in medical industry. Food & Drug Administration (FDA) approval for the treatments with tailored medicines is gaining the attention of health professionals and health care manufacturing companies.
China has involved in the launch of innovative devices which have techniques for multiple therapeutic areas. Meanwhile, Japan is also launching its new products in vitro diagnostics. Hence, Asia- Pacific is expected to capture largest share in the market owing to an increase in infectious diseases and innovation of personalized medicines. The Molecular Diagnostics Market is segmented on the basis of Product & Services, Technology, Application, End-user and Region. Based on Product & Services, the market is segmented into instruments, reagents & Kits, and software & services.
Reagents & Kits is expected to gather largest share in the market due to rising demand of reagents in clinical centers and diagnostics centers. Based on Technology, market is segmented into Polymerase Chain Reaction (PCR), Microarray, Isothermal Nucleic Acid Amplification Technology (INAAT), Hybridization, Microarray, DNA Sequencing and Next-Generation Sequencing.
Based on Application, the market is segmented into six types such as Infectious diseases molecular testing, Molecular oncology testing, Inherited diseases molecular testing, Identity testing, Tissue type testing and Pharmacogenetics testing. Infectious Diseases includes Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG), Human Papillomavirus (HPV), Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Hepatitis B, Hepatitis C, Tuberculosis (TB), Methicillin-Resistant Staphylococcus Aureus (MRSA) and other infectious diseases. On the other hand, oncology is further divided into Breast Cancer, Prostate Cancer, Colorectal Cancer and others.
The infectious diseases molecular testing is mostly preferred in the hospitals and clinical centers. Based on End-User, the market is segmented into i clinics, hospitals, laboratories, and research institutes. Based on Country, market is segmented into China, India, Japan, Australia, India, South Korea, Singapore, and Rest of Asia-Pacific.The report covers the analysis of key stake holders of the Molecular Diagnostics market. Key companies profiled in the report include Abbott Laboratories, Qiagen N.V, Roche Diagnostics, Grifols, Siemens Healthcare (Siemens AG), Becton Dickinson and Company and Danaher Corporation.